Access Report: www.scalarmarketresearch.com/market-reports/gastrointestinal-diseases-market

Gastrointestinal (also called as gastroenterology) is defined as the branch or study of the therapeutics used for the treatment of gastrointestinal (GIT) diseases. It includes diseases/disorders such as gastroesophageal reflux disease, Crohn’s disease, colon cancer, heartburn, peptic ulcer disease, inflammatory bowel disease, irritable bowel syndrome, gallstones, hemorrhoids, gastric cancer, diverticulitis, ulcerative colitis and others. These conditions are acute or chronic problems and result in clinical signs such as vomiting, ulcer development, diarrhea, constipation, bloat, and demands proper treatment therapy to cure the diseases. Diagnostic devices such as electrogastrographs (EGG), MRI and CT scan are commonly used to evaluate the gastric mobility which helps physicians to provide proper treatment for the GIT condition. Therapeutics such as Tysabri, Aciphex, Nexium are commonly commercially available drugs.

Gastrointestinal Disease Market Segmentation

The global gastrointestinal diseases market is segmented by disease types into anti-diarrhea’s, anti-emetics, proton pump inhibitors, H2 inhibitors, gastrointestinal cancer therapeutics, and others. These drugs are majorly used for the treatment of a variety of gastrointestinal disorders such as peptic ulcer diseases, irritable bowel diseases, inflammatory bowel syndrome and others. Among which, due to high incidence rate, Irritable Bowel Syndrome therapeutics market is set to record high growth rate and market revenue during the forecast period.

Get Exclusive 20% Discount @ www.scalarmarketresearch.com/get-discount.php?id=127

Table of Content

MARKET OVERVIEW
1.1. Market Definition
1.2. Research Methodology
1.3. Market Segmentation
2. EXECUTIVE SUMMARY
3. MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities
3.4. Premium Industry Trends
4. INDUSTRY ANALYSIS
4.1. Value Chain Analysis
4.2. Regulatory Analysis
4.3. Reimbursement Landscape
5. GASTROINTESTINAL DISEASES MARKET, BY DISEASE TYPES
5.1. Segment Share
5.2. Disease Types
5.2.1. Anti-Diarrhoeas
5.2.2. Anti-Emetics
5.2.3. H2 Inhibitors
5.2.4. Proton Pump Inhibitors
5.2.5. GIT Cancer Therapeutics
5.2.6. Others
6. GASTROINTESTINAL DISEASES MARKET, BY GEOGRAPHY
6.1. North America
6.1.1. By Country
6.1.1.1. U.S.
6.1.1.2. Rest of North America
6.1.2. By Disease Types
6.2. Europe
6.2.1. By Country
6.2.1.1. France
6.2.1.2. Germany
6.2.1.3. U.K.
6.2.1.4. Rest of Europe
6.2.2. By Disease Types
6.3. Asia-Pacific
6.3.1. By Country
6.3.1.1. China
6.3.1.2. India
6.3.1.3. Japan
6.3.1.4. Rest of Asia-Pacific
6.3.2. By Disease Types
6.4. Rest of the World
6.4.1. Latin America
6.4.1.1. By Disease Types
6.4.2. Middle East & Africa
6.4.2.1. By Disease Types
7. COMPETITIVE LANDSCAPE
7.1. Market Share Analysis
7.2. Key Innovator Companies
8. KEY MARKET PLAYERS
8.1. AstraZeneca
8.1.1. Overview
8.1.2. Key Strategies
8.1.3. Recent Developments
8.2. Salix Pharmaceuticals
8.2.1. Overview
8.2.2. Key Strategies
8.2.3. Recent Developments
8.3. Takeda Pharmaceutical Company Limited
8.3.1. Overview
8.3.2. Key Strategies
8.3.3. Recent Developments
8.4. Shire
8.4.1. Overview
8.4.2. Key Strategies
8.4.3. Recent Developments
8.5. Johnson & Johnson Private Limited
8.5.1. Overview
8.5.2. Key Strategies
8.5.3. Recent Developments
8.6. Eisai Co., Ltd.
8.6.1. Overview
8.6.2. Key Strategies
8.6.3. Recent Developments
8.7. Abbott
8.7.1. Overview
8.7.2. Key Strategies
8.7.3. Recent Developments
9. SCALAR 360 DEGREE MARKET PERSPECTIVE
10. APPENDIX

Get Sample Report@ www.scalarmarketresearch.com/request-sample.php?id=12